Results 41 to 50 of about 31,699 (207)

Hypothermia from a two‐component mixture comprising Amoxicillin and Sulbactam

Clinical Case Reports, 2020
Hypothermia might be an adverse effect of Amoxicillin and/or Sulbactam, and clinicians should be aware of this effect. Further clinical and laboratory investigations are also needed to confirm and clarify the underlying mechanism of this side effect.
Tung Anh Dinh Duong, Ngoc Anh Hoang, Linh Doan Thi, Dung Bui Thi, Huong Pham Thi, Sang Nguyen Ngoc, Chien Bui Van, Thuc Dinh Van   +7 more
doaj   +1 more source

Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study [PDF]

, 2023
Objective: Acute kidney injury (AKI) is a common adverse reaction observed with the clinical use of cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium.
Xiao Li, Ruiqiu Zhang, Liming Gao, Weiguo Liu, Ping Chen, Xin Huang   +5 more
core   +1 more source

A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis

Antibiotics, 2022
Extensively drug-resistant A. baumannii (XDRAB) pneumonia has a high mortality rate in hospitalized patients. One of the recommended treatments is colistin combined with sulbactam; however, the optimal dosage of sulbactam is unclear.
Chutchawan Ungthammakhun, Vasin Vasikasin, Dhitiwat Changpradub   +2 more
doaj   +1 more source

Penicillin kills chlamydia following the fusion of bacteria with Lysosomes and prevents genital inflammatory lesions in C. muridarum-infected mice [PDF]

, 2013
The obligate intracellular bacterium Chlamydia exists as two distinct forms. Elementary bodies (EBs) are infectious and extra-cellular, whereas reticulate bodies (RBs) replicate within a specialized intracellular compartment termed an ‘inclusion ...
Le Gall, SM, Colette Kanellopoulos-Langevin, Le Gall Sylvain M., Habbeddine, M, Sylvain M. Le Gall (108751), Habbeddine, Mohamed, Delarbre, C., Dumoux, M, Maud Dumoux (501153), Dumoux, Maud, Delarbre, C, Dumoux Maud, Christiane Delarbre, Hayward Richard D., Philippe Verbeke, Delarbre Christiane, Verbeke, Philippe, Kanellopoulos-Langevin Colette, Kanellopoulos-Langevin, C, Le Gall, Sylvain M, Habbeddine Mohamed, Philippe Verbeke (16975), Hayward, RD, Hayward, Richard D, Richard D Hayward, Christiane Delarbre (501155), Delarbre, Christiane, Le Gall, S.M., Habbeddine, M., Kanellopoulos-Langevin, C., Hayward, Richard D., Colette Kanellopoulos-Langevin (146985), Mohamed Habbeddine (501154), Ramsey, K., Richard D. Hayward (272234), Verbeke, P., Verbeke, P, Kanellopoulos-Langevin, Colette, Sylvain M Le Gall, Maud Dumoux, Mohamed Habbeddine, Verbeke Philippe   +41 more
core   +2 more sources

Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein

Journal of Virology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generally hijacks the cellular machinery of host cells for survival. However, how SARS-CoV-2 employs the host’s deubiquitinase to facilitate virus replication remains largely unknown.
Xin Xiao, Shifeng Li, Zhijin Zheng, Yingying Ji, Qian Du, Yibo Zuo, Ying Miao, Yukang Yuan, Hui Zheng, Fang Huang, Jun Wang   +10 more
doaj   +1 more source

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia

Antibiotics, 2022
Cefoperazone/sulbactam (CPZ/SUL) is a β-lactam and β-lactamase inhibitor combination therapy for the treatment of respiratory tract infections. Using data from a prospective, multiple-center, open-label clinical trial in 54 patients with hospital ...
Yingjie Zhou, Jing Zhang, Yuancheng Chen, Jufang Wu, Beining Guo, Xiaojie Wu, Yingyuan Zhang, Minggui Wang, Ru Ya, Hao Huang   +9 more
doaj   +1 more source

Single-Dose Pharmacokinetics of Intravenous Sulbactam in Pediatric Patients [PDF]

, 1986
The pharmacokinetics of intravenously administered sulbactam were studied in 17 pediatric patients two to 14 years of age. Single doses of 12.5 or 25 mg/kg were infused over 3 min, and in previously healthy children, mean peak plasma concentrations 5 min
Kathrin Guenin, Guenin, Kathrin, Peter Straehl, Urs B. Schaad, Straehl, Peter, Schaad, Urs B.   +5 more
core   +2 more sources

Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Antibiotics
The treatment of Acinetobacter baumannii infections remains a challenge for physicians worldwide in the 21st century. The bacterium possesses a multitude of mechanisms to escape the human immune system. The consequences of A.
Petros Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, George Samonis   +3 more
doaj   +1 more source

Changing Patterns of Resistance to Ampicillin/Sulbactam

, 1995
Objective: To report on methods to halt the increasing resistance of gram-negative organisms to ampicillin/sulbactam. Design: A before-after observational design was used to evaluate susceptibility of organisms to ampicillin/sulbactam.
Phillip F Pierce, Helen C Turner, Sally Usdin Yasuda, Mary A Young, Princy N Kumar, Joseph G Timpone   +5 more
core   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source